Viewing Study NCT04586140



Ignite Creation Date: 2024-05-06 @ 3:18 PM
Last Modification Date: 2024-10-26 @ 1:46 PM
Study NCT ID: NCT04586140
Status: COMPLETED
Last Update Posted: 2023-03-07
First Post: 2020-10-12

Brief Title: Operation of the GHPSJ Clinical Ethical Reflection Assistance Group During the COVID-19 Period
Sponsor: Fondation Hôpital Saint-Joseph
Organization: Fondation Hôpital Saint-Joseph

Study Overview

Official Title: Operation of the Groupe Hospitalier Paris Saint-Joseph Clinical Ethical Reflection Assistance Group During the COVID-19
Status: COMPLETED
Status Verified Date: 2023-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ETHICOVID
Brief Summary: Between March and May 2020 Ile-de-France hospitals faced an influx of patients infected with the COVID 19 virus Faced with the scale of the pandemic the aggressiveness of this pathology severe respiratory complications and the shortage of resuscitation beds the teams had to make difficult decisions on the therapeutic strategy the orientation of patients in the event of respiratory distress and their intensive care status To do this each establishment reflected in an emergency context on procedures for collegial deliberation and assistance in ethical reflection based on the recommendations of the National Consultative Ethics Committee and learned societies such as the French Society of Anesthesia and Resuscitation or the French Society of Support and Palliative Care

Some hospitals had already institutionalized the ethical approach upstream of the health crisis For example the Groupe dAide à la Réflexion Éthique Clinique GAREC was created in November 2005 within the Paris Saint-Joseph Hospital Group GAREC is a collegial and multidisciplinary entity made up of 8 members who intervene at the request of caregivers when a clinical situation turns out to be ethically complex He gives an advisory opinion the decision belonging to the referring physician

At the start of the COVID period GAREC changed its structure organization and operation in order to respond to the multiple issues posed by the complexity of the health situation

This study seeks to analyze the adaptation mechanisms put in place by this group during the epidemic period as well as the nature of the benefit provided to the caregivers who requested it to the patients and to their relatives

Adaptation mechanisms during the COVID period GAREC was extended to other paramedical professions psychologists nurses thus increasing from 8 to 15 members It has set up 2 weekly meetings an on-call duty and on-call duty The requests were made easier they could be done by phone by email day or night Several questions emerge What were the motivations for enlarging the group How were the members integrated into this group What were its operating methods How and by whom was it seized For what purpose Were the intervention teams multidisciplinary
Nature of the benefit provided by GAREC it will be approached by semi-structured interviews via a qualitative research method

This work is part of a broader reflective perspective

What representation of ethics underlies this device
Does the institutionalization of ethics help to enhance or make invisible what ethics owes to daily healthcare practices
To what extent does the institutionalization of clinical ethics make health institutions more human and virtuous
Under what conditions can a device like GAREC go beyond the role of ethical guarantor and transform the institution and nursing practices in the service of a collective reflective approach This study will be carried out on patient data usually collected as part of their care and on data collected through semi-structured interviews with healthcare professionals As such it fits into the perspective of grounded theory
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None